Princess Maxima Center Utrecht
- Address
- Heidelberglann 25, 3584CS Utrecht, The Netherlands
Princess Maxima Center Utrecht - Pediatric Oncology and Rare Disease Research
The Princess Maxima Center Utrecht is a specialized pediatric research institution focused on advancing treatments for childhood cancers and rare genetic diseases. The center demonstrates expertise in conducting innovative clinical trials involving gene therapy, targeted immunotherapy, and transplant-related complications in pediatric populations.
- High-risk relapsed neuroblastoma treatment development through platform trial methodologies
- Gene therapy and long-term follow-up for cerebral adrenoleukodystrophy (CALD)
- Hematopoietic stem cell transplant complications including thrombotic microangiopathy and chronic graft versus host disease
The center's research portfolio highlights a commitment to addressing critical unmet needs in pediatric rare diseases and childhood malignancies. Their work encompasses early-phase dose-finding studies in children as young as one year of age, demonstrating specialized expertise in pediatric pharmacokinetics and safety monitoring. The center's involvement in multi-arm platform trials for relapsed neuroblastoma reflects their leadership in adaptive trial designs that accelerate access to novel therapies for children with difficult-to-treat cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Omeros Corp.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Princess Maxima Center Utrecht
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| AALL2131/EsPhALL2022, An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitor with Blinatumomab in Patients with Newly Diagnosed Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia | Universita Degli Studi Di Milano Bicocca | Phase III | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bevacizumab | 1 | Unknown | 2026-07-08 | 2026-07-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.